Literature DB >> 22362382

Combination of EGFR and COX-2 inhibitors in breast cancer patient.

Viroj Wiwanitkit1.   

Abstract

Ther combination of EGFR and COX-2 inhibitors in breast cancer patient treatment is a topic of interest. In this work, the author discusses on the synergistic effect of concomitant usage of the two drugs and also further notes on the myth in using this combination.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22362382     DOI： 10.1007/s13277-012-0345-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  4 in total

Review 1.  COX-2 as a target for cancer chemotherapy.

Authors:  Nilanjan Ghosh; Rituparna Chaki; Vivekananda Mandal; Subhash C Mandal
Journal:  Pharmacol Rep       Date:  2010 Mar-Apr       Impact factor: 3.024

2.  Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.

Authors:  Claudia Bocca; Francesca Bozzo; Stefania Cannito; Maurizio Parola; Antonella Miglietta
Journal:  Mol Carcinog       Date:  2011-08-31       Impact factor: 4.784

3.  Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.

Authors:  Ying-Xue Wang; Jin-Xiang Gao; Xiu-Yun Wang; Li Zhang; Chang-Mei Liu
Journal:  Tumour Biol       Date:  2012-01-18

Review 4.  Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.

Authors:  Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2007-09       Impact factor: 6.150
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.